Eli Lilly

Welcome to the 'Eli Lilly' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'Eli Lilly'.

Latest blogosphere posts tagged “Eli Lilly”

• (BMY) Bristol-Myers Squibb Earns FDA Approval

  
  Stock Blog Hub — Authority: 164
  Recently, Bristol-Myers Squibb Co . ( BMY ) received approval from the U.S. Food and Drug Administration (FDA) to market Abilify (aripiprazole) for the treatment of irritability in pediatric patients having autistic disorder. Abilify can be used to treat children aged 6 to 17 years for symptoms of aggression toward ...
  5 days ago

• (AZN) AstraZeneca Seeks U.S. Food and Drug Administration Approval

  
  Stock Blog Hub — Authority: 164
  Recently, AstraZeneca plc ( AZN ) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its blood clot preventer Brilinta (ticagrelor). Brilinta is an oral reversible P2Y12 adenosine diphosphate receptor antagonist for arterial thrombosis aimed to compete with ...
  1 week ago

• Lilly’s Departing R&D Chief Gets A $2M Payout

  
  Pharmalot — Authority: 582
  Just as the big drugmaker gets set to slash some 5,500 jobs as part of a mammoth restructuring, the outgoing head of R&D, Steve Paul, is getting a handsome, $2 million severance payout. The 59-year-old Paul, who joined Lilly in 1993 and has headed its storied research operations for the past six years, last week ...
  1 week ago

• How We Pay for Pharma’s Crooked Dealings

  
  Unsilent Generation — Authority: 422
  As everyone knows by now, the main reason we can’t get a health reform bill enacted is because the phamaceutical and insurance industries aren’t happy with their piece of the action. This despite the fact that when politicians talk about cutting costs, what they really have in mind is cutting services to ...
  1 week ago

• Make money, make a difference with the power of crowdsourcing

  
  TechBurgh Blog and PodCast — Authority: 537
  (ARA) – Google the words “meaningful work” and you’ll find more than 1.6 million hits, ranging from tips for finding a job you can believe in, to how to find meaning in the job you already have. Perhaps it’s another side effect of the recession, but it seems that for many Americans, making money isn’t ...
  1 week ago

• The Icos Alumni Guide, Trubion CEO Resigns, OVP Leads $30M Fate Deal, & More Seattle-Area Life Sciences News

  
  Xconomy — Authority: 703
  Roundup , Biotech , people Luke Timmerman wrote: Three years have gone by since the region’s top biotech company was taken over by Eli Lilly, so it seemed like a good time to find out where all that talent migrated around the Northwest. — Icos was once the great hope for Seattle biotech, but now ...
  1 week ago

• Forced Degradation Brochure Now Available

  
  Partnerships in Clinical Trials — Authority: 116
  IIR’s Forced Degradation Forum is returning and updated with ALL NEW information and updates on the latest forced degradation insights and advances. Over the last six years, IIR’s Forced Degradation conferences have become catalysts for scientific progress and improvements in forced degradation testing and ...
  1 week ago

• Schizophrenia Profile Consistent Worldwide

  
  Psych Central News — Authority: 551
  A wide-reaching study of people with schizophrenia discovered amazing similarities in symptoms, medication, employment and sexual problems. The findings are remarkable because investigators studied more than 17,000 individuals located among health care systems in 37 different countries. The research, published in ...
  1 week ago

• ($BMY) Bristol-Myers Squibb Divests its Nutritional Segment

  
  Stock Blog Hub — Authority: 164
  Bristol-Myers Squibb Co. ( BMY ) intends to split its 83.1% holding in the Nutritional segment which operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil and other nutritional products. The move is aimed to enable the company to concentrate on its core biopharmaceutical business. ...
  1 week ago

• On The Couch… Weekend Reading

  
  Pharmalot — Authority: 582
  Hello, everyone. In between raking leaves, hanging with the short people and walking our faithful friend, we thought it might be helpful to offer you a few minutes of interesting reading. As always, there is much to track. Just the same, we have some errands to run shortly - what the weekend be without running from ...
  1 week ago

• Some Sad Facts About Todays Antidepressants

  
  Blogs — Authority: 162
      There are a lot of sad facts about todays antidepressants.  The list is a long one.  Im going to put down what I reckon are the saddest of the sad facts; others are welcome to add their own.     I want to emphasize the word "facts."  In this post I report the findings of scientific research.  Findings ...
  2 weeks ago

• Todays Antidepressants: Some Sad Facts

  
  Genius and Madness — Authority: 93
      There are a lot of sad facts about todays antidepressants.  The list is a long one.  Im going to put down what I reckon are the saddest of the sad facts; others are welcome to add their own.     I want to emphasize the word "facts."  In this post I report the findings of scientific research.  Findings ...
  2 weeks ago

• Pharmalot… Pharmalittle… Morning Edition

  
  Pharmalot — Authority: 582
  Hello, everyone. A busy day lies ahead as the FDA holds its long-awaited meeting to discuss promotion on the Internet. More on that shortly. Meanwhile, there will also be the usual deadlines and meetings to conquer, so let’s all grab a cup of stimulation and dig in. Hope your day goes well…. Lilly Pays Utah $24M ...
  2 weeks ago

• Amgens troubles keep compounding; Aranesp studies reveal greater risks

  
  DailyFinance — Authority: 797
  Filed under: Company News , Healthcare It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen ( AMGN ) just cant catch a break, nor for that matter, create one. Recently, Amgen was hit with a double whammy -- a lawsuit and an unfavorable study of the drug. On Tuesday, yet another study ...
  2 weeks ago

• Aileron’s New Class of Drugs Shown to Get Inside Cells to Block Prime Cancer Target

  
  Xconomy — Authority: 703
  Biotech , cancer , Drugs Luke Timmerman wrote: Cambridge, MA-based Aileron Therapeutics has bet the company on the idea that it has discovered a whole new class of drugs that, like RNA interference, can hit targets in the body that are beyond the reach of conventional chemical compounds and biotech ...
  2 weeks ago

• (RX) Big Pharma and Biotech – Industry Outlook

  
  Stock Blog Hub — Authority: 164
  The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent ...
  2 weeks ago

• Drug Makers Still Repeatedly Breaking the Law over "Off-Label" Promotion

  
  Blogs — Authority: 162
  As the healthcare bill moves to the U.S. Senate and the country focuses on what is best and worst about the proposed legislation, now is the time to consider serious reform of both the price and safety of prescription drugs. Concerning price, one of the best recommendations in the House bill is repeal of the bizarre ...
  2 weeks ago

• CDC to Ration Death Vaccine

  
  Future Update — Authority: 414
  November 9, 2029 —Federal health officials announced today that, because they have to ration the scarce supply of the new death vaccine, they will withhold the medication from groups that have been identified in public opinion polls to be the least deserving. The Centers for Disease Control and Prevention ...
  2 weeks ago

• The Trouble with Transparency

  
  PharmExec Blog — Authority: 416
  Jacky Law Guest blog by Jacky Law A couple of weeks ago I attended an industry awards dinner and had an interesting conversation with an eminent doctor who shall remain nameless. The doctor in question works in a highly specialized area and frequently talks about her research at conferences around the world. ...
  3 weeks ago

• Physician Payment Sunshine: Media Support Equals More Stories

  
  Policy and Medicine — Authority: 422
  Continued media coverage of the sunshine provisions in the Senate and House health care reform bills continued today as the New York Times reported that such efforts may not be enough.   (They want more stories)   The sunshine provisions require the makers of drugs, medical devices and medical ...
  3 weeks ago

Comments about Eli Lilly